<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04696978</url>
  </required_header>
  <id_info>
    <org_study_id>PND-PD</org_study_id>
    <nct_id>NCT04696978</nct_id>
  </id_info>
  <brief_title>Study for Perioperative Neurocognitive Disorders After Deep Brain Stimulation Surgery for Parkinson's Disease</brief_title>
  <official_title>Metabonomics Characteristics and Predictive Value for Perioperative Neurocognitive Disorders After Deep Brain Stimulation Surgery for Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>wenbinlu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Changhai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Perioperative neurocognitive disorders(PND) is common to see in elderly patients. Although&#xD;
      PND increases patient mortality as well as hospitalization time, apparent inflammatory&#xD;
      factors, and related mechanisms are still unknown. Metabolites could reveal chemical&#xD;
      fingerprints left behind by cellular processes, which in turn provide a new aspect to&#xD;
      understand the biological process behind. we aim to found the metabolomics can aid the&#xD;
      development of diagnostic markers of PND screening, early detection, and further, provide a&#xD;
      basis for disease prevention and treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Month</target_duration>
  <primary_outcome>
    <measure>the level of metabolomics in patients' blood sample</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>the level of metabolomics in patients' blood sample</measure>
    <time_frame>24 hours after operation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>the level of metabolomics in patients' blood sample</measure>
    <time_frame>72 hours after operation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CAM-ICU score</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CAM-ICU score</measure>
    <time_frame>24 hours after operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CAM-ICU score</measure>
    <time_frame>72 hours after operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CAM-ICU score</measure>
    <time_frame>1 month after operation</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Neurocognitive Disorders</condition>
  <arm_group>
    <arm_group_label>PND group</arm_group_label>
    <description>patients occur neurocognitive disorders according to scores in this group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NO PND group</arm_group_label>
    <description>patients do not occur neurocognitive disorders according to scores in this group</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood of patients is collected in normal patients and PND patients&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        we select Parkinson's patients undergoing elective DBS and observe who occur PND or not.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Parkinson's patients undergoing elective deep brain stimulation&#xD;
&#xD;
          -  Age ≥55 years&#xD;
&#xD;
          -  ASA physical statusⅠ-Ⅲ&#xD;
&#xD;
          -  Elementary school or above&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with ASA physical status&gt;III&#xD;
&#xD;
          -  patients with systemic immune diseases, hematological diseases (hematological tumors&#xD;
             or leukemia), patients after transplantation, malignant tumors&#xD;
&#xD;
          -  patients with metabolic diseases such as diabetes, ketoacidosis, hyperosmolar&#xD;
             syndrome, long-term hypoglycemia,gout&#xD;
&#xD;
          -  patients who refused to join the study and lost to follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>wenbin lu</last_name>
    <phone>13004162573</phone>
    <email>13004162573@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>jinjun bian, M.D</last_name>
    <phone>13601963321</phone>
    <email>jinjunbicu@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Changhai Hospital, Second Military Medical University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jinjun bian, M.D</last_name>
      <phone>13601963321</phone>
      <email>jinjunbicu@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 23, 2020</study_first_submitted>
  <study_first_submitted_qc>January 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2021</study_first_posted>
  <last_update_submitted>January 5, 2021</last_update_submitted>
  <last_update_submitted_qc>January 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Changhai Hospital</investigator_affiliation>
    <investigator_full_name>wenbinlu</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Neurocognitive Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

